KKKoichi Kamei

Koichi Kamei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koichi Kamei has a total of 285 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Poststreptococcal acute glomerulonephritis superimposed on chronic kidney disease due to dysplastic kidney in an 11-year-old boy

    by Satoshi Okada, Koichi Kamei, Kentaro Nishi, Hideaki Kitakado, Masao Ogura, Takako Yoshioka, Kentaro Ogata, Takashi Oda

    We report an 11-year-old boy with chronic kidney disease (CKD) stage 3 due to right multicystic dysplastic kidney and contralateral dysplasia who developed poststreptococcal acute glomerulonephritis (PSAGN) that rapidly progressed to kidney failure despite intensive immunosuppressive treatment. He presented with oliguria, macrohematuria, heavy proteinuria, hypocomplementemia, and an elevated antistreptolysin O titer. Initial kidney biopsy revealed diffuse endocapillary proliferation with prominent C3 deposition, subepithelial humps, and positive staining for nephritis-associated plasmin receptor (NAPlr), consistent with PSAGN. Kidney dysfunction persisted despite the administration of methylprednisolone pulse therapy, prednisolone, cyclosporine, and mycophenolate mofetil. A second biopsy at 4 months revealed focal segmental glomerulosclerosis, diffuse foot process effacement, and negative staining for NAPlr, suggesting transition from a glomerular inflammatory process to a hyperfiltration-driven structural injury. Comprehensive genetic analysis did not identify any pathogenic variants associated with bilateral dysplastic kidney. Peritoneal dialysis was initiated on day 182, and living donor kidney transplantation was performed 10 months after nephritis onset, with favorable early outcomes. This case highlights that PSAGN superimposed on CKD with reduced nephron mass may result in rapid kidney function deterioration despite aggressive treatment.

  • Open Access

    Varicella zoster virus reinfection in a patient with refractory nephrotic syndrome: A case report

    by Koichi Kamei, Tomoya Kaneda, Kentaro Nishi, Masao Ogura

    Permanent immunity to varicella zoster virus (VZV) develops following infection in most patients, with reinfections extremely rare. Here, we report a 6-year-old boy with refractory nephrotic syndrome who contracted VZV infection during B-cell depletion after rituximab treatment. Although developing febrile neutropenia, he was promptly treated with acyclovir, which was successful. The VZV immunoglobulin G antibody titer was weakly positive (3.3) by enzyme immunoassay performed 42 days after the initial diagnosis of VZV infection, confirming the presence of VZV, although antibody production was insufficient to prevent reinfection. Three years later, he was diagnosed with VZV infection again, along with the 18th relapse of nephrotic syndrome. Although promptly recovering with acyclovir, he advanced to refractory nephrotic syndrome, which required multiple immunosuppressive therapies to achieve partial remission. The present case illustrates that antibody production can be severely suppressed not only after vaccination but also after viral infection, during rituximab-induced B-cell depletion.

  • Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome

    by Taishi Nada, Koichi Kamei, Keigo Sasaki, Kentaro Nishi, Yu Kamigaki, Toru Uchimura, Aya Inaba, Masao Ogura, Shuichi Ito

    Mycophenolate mofetil (MMF) as maintenance therapy after rituximab treatment is effective in preventing relapses in children with complicated frequently relapsing or steroid-dependent nephrotic syndrome. However, once sustained remission has been achieved by MMF, the outcomes and risk of relapse after discontinuing MMF remain unclear. We conducted a two-center, retrospective study of patients with childhood-onset frequently relapsing or steroid-dependent nephrotic syndrome who discontinued MMF because of sustained remission for ≥ 2 years on maintenance MMF after rituximab treatment. Relapse, additional treatment, and risk factors for relapses after MMF discontinuation were analyzed. Sixty patients were enrolled. After tapering or discontinuation of MMF, 35 (58%) patients relapsed, and the median time from tapering to relapse was 276 days. The 50% relapse-free survival was 1.5 years using the Kaplan-Meier method. After relapses, 30 (86%) patients required reinitiation of immunosuppressants or additional rituximab treatment. The history of initial steroid-resistant nephrotic syndrome, relapses < 10 times before the first rituximab treatment with immunosuppressants, and a longer period between the last B-cell recovery and tapering MMF were significantly associated with a lower risk of relapse in a multivariate analysis using the Cox proportional hazards model (all p < 0.05). Discontinuation of MMF may be considered in selected patients with sustained remission after rituximab treatment, particularly those with identified low-risk factors for relapse. The timing of discontinuation should be individualized according to these factors and patient-specific considerations because resumption of immunosuppressants or additional rituximab treatment is frequently required after relapse following MMF discontinuation.


  • Open Access

    Live attenuated varicella vaccines in patients treated with tumor necrosis factor-alpha inhibitors: A clinical trial

    by Koichi Kamei, Masao Ogura, Ichiro Takeuchi, Hirotaka Shimizu, Katsuhiro Arai, Kensuke Shoji, Toshinao Kawai, Isao Miyairi, Atsuko Murashima, Chikara Ogimi

    Background: Live vaccines are generally contraindicated in patients treated with biological agents. However, they are often needed in this patient population. This prospective study aimed to evaluate the immunogenicity and safety of the live attenuated varicella vaccine in patients receiving tumor necrosis factor-alpha (TNF-α) inhibitors. Methods: This single-center, prospective study was conducted at the National Center for Child Health and Development and registered with the Japan Registry of Clinical Trials in accordance with the Japanese Clinical Trials Act. Patients receiving TNF-α inhibitors were enrolled. Those with varicella-specific immunoglobulin G (IgG) levels Export

  • Open Access

    Clinical practice guideline for pediatric IgA vasculitis in Japan 2023: a digest-secondary publication

    by Masaki Shimizu, Kandai Nozu, Koichi Kamei, Satoru Arai, Shinichi Ansai, Toru Igarashi, Takashi Ishige, Maki Urushihara, Toshiyuki Ohta, Masafumi Oka, et al.


  • Efficacy and Safety of Alteplase Use for Venous Catheter Thrombosis in Pediatric Patients―a Single Center Study

    by Koichi Kamei, Yuhi Takagi, Kentaro Nishi, Masao Ogura, Tetsuya Ishimaru, Naoki Shimojima, Akihiro Yoneda, Atsushi Tanioka, Ichiro Takeuchi, Hirotaka Shimizu, et al.

    Background: Urokinase is used as a thrombolytic agent to treat catheter thrombosis. However, since 2022, the supply of urokinase has diminished, and we have been using alteplase as an alternative, although its use for treating catheter thrombosis is off‐label in Japan. Methods: We performed a single‐center, retrospective study on pediatric patients with central venous catheters (CVCs), peripherally inserted central catheters (PICCs), and central venous ports (CVPs) who received alteplase for catheter thrombosis at our facility (May 2023–October 2025). Treatment involved filling the catheter (volume: 1–1.5 mL) with 600,000 U/mL (1 mg/mL) of alteplase solution and leaving it for approximately 40 min. Efficacy was evaluated as follows: (1) success on the first dose, (2) success after two or three doses, or (3) no success. (1) and (2) were defined as effective. Results: We evaluated 84 alteplase administrations in 31 patients (CVCs: 47, PICCs: 27, CVPs: 10). Success on the first dose was achieved in 55% of cases and success after two or three doses in 20% of cases, resulting in an overall efficacy rate of 75% (CVCs: 72%, PICCs: 93%, CVPs: 40%). No adverse events were observed. Conclusions: Alteplase was generally effective for treating catheter thrombosis. However, results suggest that it is less effective in CVPs than in CVCs and PICCs, and a larger sample size is necessary for confirmation. We recommend that alteplase be approved for treating catheter thrombosis in Japan.

  • Comparative efficacy of alteplase and urokinase in pharmacomechanical thrombolysis of permanent double lumen hemodialysis catheters in children

    by Yuhi Takagi, Kentaro Nishi, Manami Konishi, Satoshi Okada, Masao Ogura, Koichi Kamei

    Background Thrombotic occlusion of permanent double lumen catheters (PDLC) in hemodialysis has traditionally been treated with urokinase (UK), a thrombolytic agent. However, because UK is no longer available, alteplase has been reported as an alternative. In this study, we compared the efficacy and safety of alteplase with those of UK. Methods This retrospective analysis included patients undergoing hemodialysis with thrombotic occlusion from May 2014 to February 2025. The drug was administered as a bolus dose into the catheter and allowed to dwell for 60 min. The primary endpoint was the blockage resolution rate after the first thrombolytic agent. Results During the study period, 24 patients underwent pharmacological thrombolysis, with a total of 165 procedures performed, including 37 with alteplase and 128 with UK. The median age and weight at the time of thrombotic occlusion were significantly lower in the alteplase group than in the UK group (1.7 vs. 3.9 years and 6.4 vs. 14.4 kg; p < 0.01). The alteplase group had a higher success rate (34/37, 94%) than the UK group (96/128, 75%) (p = 0.038). When the first dose of alteplase was unsuccessful, a second dose successfully cleared the blockage in all instances. No serious adverse effects, such as bleeding events, were observed in either group. Conclusions Alteplase may serve as a viable alternative in settings where UK is unavailable. Its bolus administration, established as safe in adults, also appears to be safe in children weighing less than 10 kg, with no serious adverse events observed. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information